TLDR
- Sanofi agreed to pay Regeneron $1 billion upfront and up to $7 billion more in milestone payments.
- The deal expands their partnership to four new antibody drugs for inflammatory diseases.
- Sanofi stock rose as much as 3.6% before settling around 1% higher.
- The companies also settled a prior legal dispute tied to their partnership.
- Regeneron will lead research and development, Sanofi will lead global sales.
Sanofi (SNY) stock climbed as much as 3.6% on Thursday before settling to a gain of about 1% after the French drugmaker struck a new deal with Regeneron (REGN). The agreement expands their existing partnership to cover four new antibody-based medicines.
Sanofi will pay $1 billion upfront. Another $7 billion could follow depending on how the drugs perform in development, regulatory reviews, and sales.
The four medicines target inflammatory diseases linked to the immune system. This is the same type of science behind Dupixent, the companies’ blockbuster eczema drug used by more than 1.5 million patients.
What the New Drugs Target
The first drug, REGN20423, is already in early testing for atopic dermatitis. That’s a common inflammatory skin condition.
The other three medicines haven’t reached human trials yet. Two are still in early development, with testing expected to start in 2027.
Regeneron will lead the research and development work on these drugs. Sanofi will take charge of selling them worldwide once approved.
The two companies will split both costs and profits equally. That structure mirrors how they already work together on Dupixent.
Dupixent itself isn’t changing. The existing agreement on that drug stays exactly as it was before this new deal.
Regeneron also picked up an option on Sanofi’s own pipeline. It can choose to join Sanofi’s experimental drug lunsekimig once late-stage trials wrap up.
That drug is being tested for chronic obstructive pulmonary disease, or COPD. It’s a separate bet outside the immune-disease bucket covered by the main deal.
Why Sanofi Is Doing This Now
Sanofi has called the deal a first step toward rebuilding its drug pipeline. Dupixent’s patent protection won’t last forever, and the company wants replacements lined up.
Analysts at Jefferies framed it as a signal about leadership. They wrote that the expansion “should be viewed positively, as it signals the new CEO’s proactive focus on the most important yet addressable uncertainties investors face.”
In plain terms, Wall Street sees this as Sanofi’s new boss getting ahead of a problem rather than waiting for it to show up on the balance sheet.
The deal isn’t just about new science, though. The two companies also settled an earlier legal dispute connected to their partnership.
Neither side gave details on what that dispute was about or what the settlement terms involve. The companies simply confirmed it’s now resolved.
Sanofi shares were trading at $41.23 as of the latest check, up 1.20% on the day. Regeneron stock also moved higher, gaining 1.03%.
The news broke early Thursday and sent both stocks up in morning trading. Investors appear to be reading the expanded deal as a sign of stability between the two longtime partners.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
